Raut Serums India Pvt. Ltd. has been honoured with the India Pharma Award 2025 for its innovative Snake Bite Venom Detection Kit. The award was received by Dr. Anil Yadav on behalf of the Raut Serums Ind Pvt. Ltd. at a ceremony held in Delhi. This recognition highlights Raut Serums commitment to developing life-saving solutions that strengthen emergency and rural healthcare systems.
India has achieved an unprecedented milestone in the field of snakebite management and public health by successfully developing the world’s first Rapid Snake Venom Detection Kit (SVDK). This landmark innovation represents a historic breakthrough not only for India but also for global healthcare systems addressing snakebite envenomation.
This pioneering achievement has been jointly realized by the following three Indian companies, who together have made a transformative contribution to healthcare innovation:
Snakebite envenomation remains a major public health challenge, particularly in rural, tribal, and remote regions, where delayed diagnosis and inappropriate treatment result in significant morbidity and mortality.
In snakebite cases, every minute is critical. A rapid and accurate determination of whether venom has been injected is essential for making correct clinical decisions. Until now, the absence of such diagnostic capability often led to:
The SVDK addresses this critical gap by providing rapid, reliable, and precise detection of snake venom within minutes, enabling clinicians to determine:
This ensures timely, evidence-based, and safe clinical intervention, while preventing unnecessary or excessive use of antivenom.
For rural farmers, tribal communities, and economically disadvantaged families, the SVDK functions as a true life-saving intervention.
This globally significant innovation was achieved through exceptional scientific leadership, technical expertise, and collaborative effort:
Technical Leadership & Scientific Guidance
Patent Holder:
Manufacturing site At.
The global importance and innovation value of the SVDK were formally recognized at the CPHI & PMEC Pharma Awards 2025, held in New Delhi on 25 November 2025.
Award Received:
Pharma Innovation of the Year – Product (Pharma Award 2025)
By winning this prestigious international award, the three collaborating companies have demonstrated India’s leadership in healthcare innovation and translational research on a global platform.
Recognizing the clinical value, public health relevance, and social impact of the SVDK, the Government of Maharashtra has taken a landmark policy decision.
With the approval of:
The state government has approved the procurement of 1,10,213 SVDK kits.
These kits will be distributed free of cost across: Maharashtra
This initiative is expected to save thousands of lives by ensuring early, accurate diagnosis and rational treatment of snakebite cases throughout Maharashtra.
The SVDK is fully aligned with international and national public health strategies, including:
The fundamental goals of the SVDK initiative are:
Through the development of the SVDK, India has not merely created a diagnostic innovation—India has saved lives.
This achievement stands as a source of national pride and marks a new milestone in Indian biomedical research, diagnostics, and public healthcare delivery.
